

This Document can be made available
in alternative formats upon request

State of Minnesota
HOUSE OF REPRESENTATIVES

EIGHTY-SIXTH
SESSION

HOUSE FILE No. **358**

January 29, 2009

Authored by Ruud, Thissen, Mullery and Hamilton

The bill was read for the first time and referred to the Committee on Health Care and Human Services Policy and Oversight

1.1 A bill for an act
1.2 relating to insurance; limiting excessive co-payments on drugs to treat multiple
1.3 sclerosis; proposing coding for new law in Minnesota Statutes, chapter 62Q.

1.4 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

1.5 Section 1. **[62Q.528] MULTIPLE SCLEROSIS DRUGS; CO-PAYMENTS**
1.6 **LIMITED.**

1.7 (a) For purposes of this section, "multiple sclerosis drug" means a drug that is
1.8 approved by the federal Food and Drug Administration for the treatment of multiple
1.9 sclerosis.

1.10 (b) No health plan, as defined in section 62Q.01, subdivision 3, may assess a
1.11 co-payment in excess of \$50 per 30-day supply of a multiple sclerosis drug.

1.12 (c) Paragraph (b) does not apply if the multiple sclerosis drug has a less expensive
1.13 generic equivalent approved by the federal Food and Drug Administration for treatment
1.14 of multiple sclerosis which the patient's treating physician for multiple sclerosis has
1.15 determined is equally safe and effective for the patient.

1.16 **EFFECTIVE DATE.** This section is effective August 1, 2009, and applies to health
1.17 plans issued, renewed, or continued as defined in section 60A.02, subdivision 2a, on or
1.18 after that date.